Gilead's Kite Receives Expanded Approval for its CAR-T Yescarta's in Follicular Lymphoma Gilead’s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or ...
Find MorePeanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage. The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...
Find MoreThe interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!